March 15, 2021 Life Science Tools PR/Corporate

Bio-Techne Announces ISO 9001:2015 Certification for Its Bristol Manufacturing Facility.

MARCH 15, 2021 MINNEAPOLIS, March 15, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that its Bristol site in the United Kingdom received ISO 9001:2015 Quality Management Systems certification. Bio-Techne’s Bristol facility produces life science reagents for... Read more

February 23, 2021 Clinical Research/Diagn. M&A, Partnerships

Bio-Techne and Luminary Therapeutics Sign License Agreement for Use of Bio-Techne’s TcBuster for the Development of Luminary’s CAR-T Cell Therapies

FEBRUARY 23, 2021 MINNEAPOLIS, Feb. 23, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne’s proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing.   Under the terms of this agreement,... Read more

January 28, 2021 Clinical Research/Diagn. M&A, Partnerships

Bio-Techne Announces Strategic Investment in Eminence

MINNEAPOLIS, Jan. 28, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced an initial minority strategic equity investment in Changzhou Eminence Biotechnology Co., Ltd. (“Eminence”).  Eminence will use the financing proceeds to expand its manufacturing capacity and increase the... Read more

December 2, 2020 Clinical Research/Diagn. M&A, Partnerships

Regulus Therapeutics Collaborates with Bio-Techne for Biomarker Development

MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment. Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to aid in their clinical trial... Read more

October 19, 2020 Clinical Research/Diagn. Life Science Tools Product Launch

Bio-Techne Announces Commercial Release of New SARS-CoV-2 Multi-antigen Serology Assay Kit for Simple Western

New serology assay accelerates COVID-19 research and vaccine development through rapid characterization of human immune response to multiple SARS-CoV-2 antigens MINNEAPOLIS, Oct. 19, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module for Jess and Wes Simple Western automated western blotting systems.  The SARS-CoV-2 multi-antigen... Read more

October 1, 2020 Life Science Tools PR/Corporate

Bio-Techne Announces Opening of New Canadian Facility

MINNEAPOLIS, Oct. 1, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Canadian office located in Toronto. This new office will be the workplace for approximately 40 Bio-Techne employees and reflects the Company’s commitment to supporting the Canadian life sciences industry as well as expectations for continued growth in this geography. The... Read more

September 30, 2020 Life Science Tools PR/Corporate

Bio-Techne Announces Grand Opening of GMP Manufacturing Facility

MINNEAPOLIS, Sept. 30, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufacturing Practices) manufacturing facility. Located in St. Paul, MN, the new facility is dedicated to supporting large-scale production of GMP-grade materials, including E. coli-derived recombinant proteins, which are an essential component for... Read more

September 21, 2020 PR/Corporate

Bio-Techne Rebrands B-MoGen Biotechnologies as Part of the R&D Systems Product Portfolio

MINNEAPOLIS, Sept. 21, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services, and its proprietary transposon-transposase gene transfer system, TcBuster™, will be rebranded as R&D Systems. As part of the rebranding, the B-MoGen Biotechnologies website will be retired. Service details and purchasing... Read more

September 17, 2020 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Bio-Techne and QIAGEN Announce Expansion and Extension of Exosome Partnership

MINNEAPOLIS, Sept. 17, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V. today announced the expansion and extension of a non-exclusive partnership to co-market exosome technology to existing and potential biopharma partners as well as the joint development of new exosome based products.   The agreement grants QIAGEN a non-exclusive development license to Bio-Techne’s exosome... Read more

August 19, 2020 Life Science Tools M&A, Partnerships

Bio-Techne Corporation and Leica Biosystems Are Accelerating Disease Research With RNAscope Covid-19 Probes and the Bond Rx*

AUGUST 19, 2020 Research-use-only RNA-ISH probes now available for COVID-19 on our automated platform MINNEAPOLIS, Aug. 19, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH), in partnership with Leica Biosystems, today announced the automation of RNAscope™ COVID-19 probes on BOND RX*, Leica’s staining platform, for research use only. Researchers now have the ability to automate their COVID-19 research protocols,... Read more